Protocol Ledger

NCT06890533 · Phase III · ACTIVE NOT RECRUITING

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery

Interventional Phase III clinical trial protocol NCT06890533 sponsored by Shanghai Haiyan Pharmaceutical Technology Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-14 Enrollment: 560 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06890533
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)560 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06890533
Protocol FieldVerified Registry Value
NCT IdentifierNCT06890533
Consolidated Lead SponsorShanghai Haiyan Pharmaceutical Technology Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment560 participants (ESTIMATED)
Registered Start Date2025-05-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI